Dyadic International Inc., Jupiter, Fla., a global biotechnology company focused on the discovery, development, manufacture and sale of enzymes and other proteins for the industrial enzyme, bioenergy, bio-based chemical and biopharmaceutical industries, has announced that its research and development center in Wageningen, Netherlands, is a participant in the HealthBread Project, a new multidisciplinary research program that has been awarded approximately 1 million euros from the European Community’s Seventh Framework Programme (FP7).
The HealthBread Project is a two-year research program whose objective is to develop whole-grain and white breads with improved nutritional value, taste and product quality by applying scientific and technological knowledge to the production and marketing of commercially viable, healthier bread. Dyadic Netherlands will receive approximately 143,000 euros to develop commercial enzymes for the HealthBread Project, which is scheduled to begin in October 2012.
“In continuing to enhance Dyadic's technologies and products for food applications, we are excited to work with leading scientific, baking and food organizations to demonstrate the effectiveness of Dyadic's C1 enzyme technology in producing healthier and more nutritious bread products,” states Wim van der Wilden, general manager of Dyadic Netherlands. “The value of these types of research programs is that they allow Dyadic to use and further enhance our technologies for specific enzyme applications in collaboration with leading organizations which can potentially lead to new sales and licensing opportunities."
The Netherlands Organization for Applied Scientific Research (TNO) will serve as coordinator of the HealthBread Project which, in addition to Dyadic Netherlands, consists of research organizations, bakeries and large ingredient suppliers in Austria, Finland, Germany, Italy and the Netherlands.
Source: Dyadic International Inc.